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ABSTRACT 
 
During viral replication, herpesviruses package their DNA into the procapsid by 
means of the terminase protein complex. In human cytomegalovirus (herpesvirus 
5), the terminase is composed by subunits UL89 and UL56. UL89 cleaves the long 
DNA concatemers into unit-length genomes of appropriate length for 
encapsidation. We used ESPRIT, a high-throughput screening method, to identify 
a soluble purifiable fragment of UL89 from a library of 18,432 randomly truncated 
ul89 gene constructs. The purified protein was crystallized and its three-
dimensional structure was solved. This protein corresponds to the key nuclease 
domain of the terminase and shows an RNase H/integrase-like fold. We 
demonstrate that UL89-C has the capacity to process the DNA and that this 
function is dependent on Mn
2+
 ions, two of which are located at the active site 
pocket. We also show that the nuclease function can be inactivated by raltegravir, 
a recently approved anti-AIDS drug that targets the HIV integrase.  
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INTRODUCTION 
 
Human cytomegalovirus (HCMV) is a member of the herpes family of viruses or 
Herpesviridae. This group includes the human pathogens herpes simplex virus type 1 
and 2, varicella zoster virus, Epstein-Barr virus, cytomegalovirus, roseolovirus, and 
Kaposi’s sarcoma-associated herpesvirus. Among these, HCMV, which belongs to the 
Betaherpesviridae subfamily, is widespread throughout the human population and 
causes the most morbidity and mortality. HCMV infection is rarely serious for people 
with a competent immune system, although it persists in the host cells and propagates to 
other individuals. In contrast, infection or reactivation of HCMV is a major cause of 
life-threatening complications in immunocompromised individuals, such as organ 
transplant recipients and leukemia or AIDS patients, and is the most significant viral 
cause of birth defects in industrialized countries (1). 
 
The HCMV genome consists of linear double-stranded (ds) DNA of 230 kb with the 
highest coding-capacity among Herpesviridae. HCMV, like all other herpesviruses, 
replicates its genomic DNA into high molecular mass head-to-tail concatemers. The 
newly synthesized multi-copy chains of DNA are then excised into unit-length genomes 
and each genome is packaged singly into one viral procapsid (2). Maturation into unit-
length genome molecules involves viral DNA recognition and cleavage at the site-
specific pac motifs, which are redundant motifs found at both the 5′ and 3′ genomic 
termini (2, 3). The dsDNA endonuclease and packaging activities are performed by a 
protein complex, the terminase, composed by subunits UL56 and UL89 (4, 5). UL56 
has been reported to recognize the pac motif (6).    
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After cleaving one end of the DNA, the terminase translocates the viral DNA into the 
procapsid, deriving energy for this process through ATP hydrolysis. The procapsid is 
filled with the DNA molecule and the terminase performs a second dsDNA cleavage, 
thereby concluding the translocation (3). UL89 has predicted ATPase activity and is 
most probably the molecular motor for helicase-like DNA translocation (7). In addition, 
UL89 binds and cleaves DNA molecules, and this activity is enhanced when UL56 is 
present (5). In agreement, other studies have shown that UL89 interacts specifically 
with the C-terminal part of UL56 (8). UL56 has the capacity to bind linearized DNA but 
only upon addition of UL89 is the DNA cut into smaller fragments. This observation 
indicates that these proteins mediate a concerted reaction of DNA recognition and 
cleavage (5). 
 
Proteins homologous to UL89 are known in all herpesviruses, as are the other terminase 
subunits, thus indicating that the DNA packaging mechanism is highly conserved (9). 
The ul89 ORF includes two exons separated by a 3902-bp intron. It encodes a two-
domain 674 amino acid protein with predicted N-terminal ATPase and C-terminal 
nuclease activity (Fig. S1) (7). Bacteriophages translocate shorter DNA molecules into 
their capsids by similar packaging systems (9). Their terminases have been intensively 
studied, in particular those of phages T4 and RB49(10), (11), SPP1(12), P22(13) and 
Sf6(14), and the structure of the nuclease domains of the large terminase subunits gp17 
of RB49 (15) and G2P of SPP1(16) and the full-length large terminase subunit gp17 of 
T4 (15) have been determined. A theoretical model for the structure of the C-terminal 
domain of UL89 has been proposed recently (17). 
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Several studies report inhibitors that prevent the formation of new virions through 
blockage of the termination system (18-22). However, the structural and functional 
characterization of herpes packaging proteins, which could assist further discovery and 
development of novel antiviral molecules, has been hindered by the difficulties in 
expressing enough soluble material for structural analysis. We have overcome these 
problems by using ESPRIT (23, 24), a combinatorial library method for defining 
soluble constructs through random gene truncation and expression screening. This 
approach yielded a single active soluble construct corresponding to the C-terminal 
nuclease domain of UL89, the structure of which we report herein at a resolution of 2.15 
Å. As such, it is the first protein domain structure reported from the herpesvirus 
terminase. 
 
 
RESULTS 
 
Expression of UL89 with a library-based construct screen 
The two exons of the HCMV ul89 gene were cloned as a single DNA construct and 
initially tested for protein expression in several E. coli strains and conditions. No 
protein obtained from these assays was stable enough to withstand purification. Similar 
results were obtained when the full-length gene was expressed in insect or mammalian 
cells. Extensive trials with refolding protocols were also unsuccessful. A number of 
constructs for each putative domain were designed, based on secondary structure 
prediction, globularity and disorder, but none of them expressed soluble protein in any 
system or condition assayed.  
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Subsequently, in order to find soluble domains, we used the combinatorial library 
method ESPRIT (23, 24), which generates comprehensive libraries of 5′ or 3′ truncated 
genetic constructs of the target. Both libraries were synthesized from the ul89 gene. We 
then screened 9216 clones for each library form, corresponding to an approximate four-
fold oversample of all possible domain boundaries, for expression of soluble protein. 
The two libraries were arrayed onto the same nitrocellulose membrane, and colonies 
were screened for putative soluble protein expression in colony format using 
measurements of in vivo biotinylation efficiency of a C-terminal biotin acceptor peptide 
by fluorescent streptavidin hybridization (23). Although a relatively large number of 
clones exhibited positive signals in the 3′ truncation library, small-scale 4-ml liquid 
expression trials yielded only marginally soluble uninteresting fragments of less than 20 
kDa in size. In contrast, the 5′ truncation library yielded several partially soluble, 
purifiable constructs of similar size (approximately 37 kDa), from which the 48K22 
construct was selected as showing the best behavior following scale-up testing (Fig. 
S1). This construct was only partially soluble (estimated at 5% of total UL89 protein), 
but was stable through scale-up to 12 liter culture volumes and yielded approximately 1 
mg of purifiable monodisperse protein per liter of culture. Other similar-sized constructs 
identified as partially soluble in small-scale testing did not maintain solubility during 
subsequent scale-up steps. Subsequent DNA sequencing and mass spectrometry 
fingerprinting identified construct 48K22 as a C-terminal fragment of UL89 (residues 
418 to 674; Fig. S1), hereafter termed UL89-C. This fragment falls inside the predicted 
C-terminal nuclease domain, encoded in exon 2. 
 
 7 
Overall structure of UL89-C 
UL89-C displays a wedged shape with dimensions 40 × 35 × 46 Å. A central eight-
stranded mixed β-sheet, with parallel and anti-parallel strands, is flanked by helices α on 
both sides (Fig. 1A). At one side, hydrophobic interactions pack α2 and α3 against the 
sheet. At the other site, helices α1, α4, α5 and α6 form a bunch that interacts with the β-
sheet by hydrophobic interactions from one side of 5 and 6 and by hydrophilic 
contacts made by the α1 and α4 C-terminal ends. Two 310 helices, 1 and 2, at loops 
connecting 1 to 2 and 6 to 10, border one end of the -sheet. The strand order in 
the central sheet is 1, 9, 4, 3, 2, 5, 6, and 10 with topology +4,-1,-1,+3x,+1x,-5x,+6 
(25)(Fig. 1C and Fig. S2). At both lateral edges of the -sheet, β1 and β10 form short 
strands of only three amino acids each. At one end of the  sheet, long loops surround a 
cleft that typically harbors the active site in proteins sharing this fold. One of these 
loops flanking the active site cavity folds in a twisted β-hairpin, formed by and 
(Fig. 1A).  
 
UL89-C belongs to the RNase H-like superfamily  
A search for structurally similar proteins revealed that UL89-C has the characteristic 
fold of the RNase H-like superfamily of nucleases and polynucleotidyl transferases 
(26). The closest structural relatives to UL89-C are the recently reported nuclease 
domains of the large terminase subunits of bacteriophages, RB49 and T4 gp17 
(15)(RMSD 2.6 Å for 158 equivalent C  and 2.7 Å for 159 equivalent C , respectively) 
and SPP1 G2P(16) (RMSD 3.0 Å for 146 equivalent C ), the Holliday junction 
resolvase RuvC(27) (RMSD 2.6 Å for 115 equivalent C ), the HIV-integrase(28, 29) 
(RMSD 2.6 Å for 78 equivalent C
α
) and the ASV-integrase(30) (RMSD 2.9 Å for 85 
equivalent C
α
). The crystal structures of all these proteins and other members of the 
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superfamily display the same basic fold but vary in length and show almost no amino 
acid sequence identity (i.e., 7.7% identity between UL89-C and the closest structural 
relative, the nuclease domain of RB49 gp17, after structural alignment). The structural 
homology between these enzymes can be well described from the structural pattern of 
human RNase H1 (Hs-RNase H1) (31), which consists of a five-stranded β sheet 
surrounded by α helices on both sides. The order and orientation of the strands within 
the β-sheet is conserved: 3, 2, 1, 4 and 5, one of them being anti-parallel to the other 
four (↑↓↑↑↑). These strands are equivalent to the UL89-C -strands 4, 3, 2, 5 and 6, 
respectively, while helices A, B and E Hs-RNase H1 correspond to helices 2, 3 
and  of UL89-C. All these elements are arranged similarly in all proteins of the 
superfamily, except for 6 ( E in Hs-RNase H1) which runs in the opposite direction in 
UL89-C, RB49 gp17, SPP1 G2P and RuvC with respect to the other members of the 
superfamily (Fig. S3). UL89-C (257 aa) is larger than the bacteriophage homologous 
proteins gp17 (206 aa) (15) and G2P (178 aa) (16). It is also larger and more complex 
than RNase H, integrase or resolvase nuclease domains, with the central -sheet 
composed by 8 strands rather than 5, and further  helices and other secondary structure 
elements. Other members of the superfamily, like Tn5 transposase (32, 33) and Piwi-
Argonaute (34), also have additional structural elements around the basic RNase H fold, 
although they are quite different from those found in UL89, thus reflecting their diverse 
functions, substrates and interactions with other proteins. 
 
Active site cleft 
The active site is located at one end of the central -sheet in a cleft formed by conserved 
residues, four of them acidic (Fig. 1B). In all structures with a RNAse-like fold, the 
active site is located at a topologically equivalent position, at one end of the -sheet 
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where two parallel -strands ( 2 and 5) separate in a fork-like manner. Asp463, 
Glu534, and Asp651 coordinate two metal cations (see below). Asp463 is located at the 
C-terminal end of β2 while Glu534 is present at the end of β5. Asp651 is found at the 
beginning of α6, the last -helix in the structure, which lies diagonally to the two -
strands on one of the faces of the central -sheet (Fig. 1). These three acidic amino acids 
are fully conserved and confer a strong electronegative character to the active site (Fig. 
2 & Fig. S2). A further conserved aspartate residue, Asp650, is located close to the 
active site cleft (Fig. 1B) but does not interact directly with any of the metal ions. 
Comparison of the active site of UL89-C with other RNAse-like nucleases (Fig. S3) 
shows that the presence of several acidic residues coordinating metal ion is a signature 
of the superfamily, in particular the central residue is always an aspartate (Asp463 in 
UL89-C). The other residues coordinating the metal may vary. For example in 
bacteriophage SPP1 G2P(16), one of the closest structural relatives to UL89, an 
aspartate residue (Asp321) occupies a position equivalent to Glu534 in UL89-C and a 
histidine residue (His400) that of Asp651. However, in T4 and RB49 gp17(16) the 
residues coordinating the metal ion are identical to those of UL89-C (Fig. S3). 
Moreover, in these structures an aspartate residue occupies the equivalent position of 
Asp650 in UL89-C, although two additional acidic residues of the active pocket present 
in the bacteriophage structures, Asp 406 and Glu401 in RB49 gp17, are not present in 
UL89-C.     
 
The active site accommodates two cations  
In the crystal not soaked with MnCl2, one metal ion was clearly identified at the active 
site. This corresponds to metal B, as defined by Nowotny & Yang (35). In molecule D 
of this crystal, an electron density peak initially assigned as a water molecule (the 
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strongest peak of the water list) could also correspond to another metal ion located at a 
second position with low occupancy. Indeed, an anomalous difference map calculated 
from diffraction data from a crystal soaked with MnCl2 showed two peaks at these two 
positions (Fig. S4). The first one is coordinated by Asp463 and Glu534 and the second 
by Asp463 and Asp 651 (Fig. 1B). Asp463, Glu534 and Asp651 (and the closest 
residues Pro464, Ala465, Gly535, Asn536 and Asp650) are fully conserved among 
human herpesvirus terminases (Fig. S2), thereby suggesting that they are essential for 
cation coordination and thus for catalysis. Indeed, Mg
2+
 or Mn
2+
 cations are required for 
the functioning of these enzymes and a two-metal catalysis has been proposed for their 
enzymatic mechanism (35, 36). 
 
In vitro nuclease assays and mutants 
An in vitro assay demonstrated that UL89-C has the capacity to degrade linear and 
circular DNA and this function is strongly activated by Mn
2+
 (Fig. 3A and B). In the 
presence of this cation, UL89-C converts supercoiled circular plasmid DNA to nicked 
open circular DNA, subsequently to linear DNA and finally to completely degraded 
DNA (Fig. S5). Similarly, UL89-C also degrades linear DNA (Fig. 3A and C). Similar 
behavior was previously described for the UL89 full-length protein (5). The reaction 
performed in the same conditions but in the presence of Mg
2+ 
instead of Mn
2+
 converted 
only supercoiled circular plasmid to nicked open circular DNA. With Ca
2+
, the DNA 
degradation was even less efficient (Fig. 3A and B). In order to verify that the residues 
of the structurally-inferred active site were truly involved in the nuclease activity of the 
protein, we designed a set of single and double mutants and tested their activity. The 
single mutants D463A, D651A and the double mutant D463A/E534A showed only 
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residual activity (Fig. 3C and D). These results confirmed that UL89-C harbors the 
nuclease activity critical for the full length protein performance. 
 
Inactivation by raltegravir 
The structural similarity between the herpesvirus terminase nuclease domain and the 
HIV integrase prompted us to test the inhibitory properties of integrase inhibitors on 
UL89-C. One of these integrase inhibitors, raltegravir (MK0518), was approved by the 
FDA in 2007 for the treatment of AIDS (37). Raltegravir turned out to be a strong 
inhibitor of the nuclease activity of UL89-C (Fig. 4). A recent structure of the prototype 
foamy virus integrase in complex with DNA and the inhibitor shows that raltegravir 
binds at the active site, directly coordinating the metal ions (38). Presumably, it would 
bind in a similar way to UL89-C. In contrast to raltegravir, another integrase inhibitor, 
elvitegravir (GS9137), had no inhibitory effect on UL89-C under similar conditions. 
 
DISCUSSION 
A powerful construct screening technique to obtain UL89-C 
UL89, like other herpesvirus DNA packaging proteins, is scarcely expressed in a 
soluble, purifiable form. Even using insect or mammalian eukaryotic expression 
systems, we and others were unable to purify a soluble form of this protein in sufficient 
amounts for crystallographic or even limited proteolysis studies. The ESPRIT (23, 24) 
analysis reported here permitted the oversampling of all possible domain boundaries as 
hexahistidine tag fusion positions. However, even this approach resulted in a very low 
number of soluble expression constructs. This finding is indicative of the challenging 
nature of UL89. The resulting construct encoding the UL89 C-terminal domain 
expressed protein that was partially soluble, but the purifiable material was 
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monodisperse and well-behaving through subsequent concentration and crystallization 
steps. The identification of this otherwise obscure expression-compatible construct is 
illustrative of the power of this technique to find rare soluble forms of difficult proteins, 
and this approach appears particularly effective for viral proteins with uncertain domain 
boundaries (39). 
 
DNA binding 
UL89-C cleaves dsDNA in vitro (Fig. 3), as reported previously for the full-length 
protein (5). This domain should bear the structural determinants for DNA binding. An 
electrostatic surface calculation indicates that a number of positively charged residues, 
located in different loops, surround the active site cleft (Fig. 2B). From this calculation, 
the shape of the surface, and superpositions with B. halodurans (40) and human RNase 
H structures in complex with a DNA/RNA hybrid (31) and Tn5 transposase in complex 
with DNA (33), we manually built a model for dsDNA bound to UL89-C (Fig. S6). In 
this model, the loops L 2- and L 5- 3 fit into the major groove of the DNA, while 
positively charged side chains appear in close proximity to the phosphates. The sugar-
phosphate backbone enters the active site but does not get close enough to the metal ion 
positions. A distortion (bent) from the regular straight B-DNA used in the model would 
be necessary for the scissile phosphate to reach the metal ions without clashes of the 
DNA with the active site surrounding loops. In the bacteriophage large terminase 
structures, some of these loops, i.e 2- 9 and 5- 3, are shorter or less protruding, 
resulting in a slightly less deep active site. However, Smits et al. (16) reported that a 
protruding -hairpin in the SPP1 G2P structure would clash with the DNA and 
suggested that the conformation of this loop changes upon DNA binding. This loop 
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corresponds to loop 5- 6 in ULC89-C, which was disordered and not visible in our 
structure, in agreement with its proposed flexibility. 
 
In RNase H, the equivalent loops to UL89 L 2- 3 and L 5- 3 contact the minor 
groove of the RNA/DNA hybrid, instead of the major groove of the dsDNA, as in our 
DNA-UL89-C docking model. This observation is not contradictory because the 
conformation of the RNA/DNA hybrid is a mixture between A and B forms, where the 
minor groove is wider and the bases are accessible. However, the viral dsDNA is most 
probably in the B-conformation (albeit probably distorted) where the minor groove is 
too narrow to permit the entrance of loops L 2- 3 and L 5- 3. Therefore, interaction 
with the bases, if present, would be performed through the major groove. Indeed, loop 
L 5- 3 is longer and more protruding than its RNase H equivalent. The shallow 
RNA/DNA hybrid minor groove cannot accommodate this loop, but a deeper B-DNA 
major groove would fit (Fig. S6). 
 
UL89-C within the terminase complex 
In the crystal structure, UL89-C shows four protein molecules in the asymmetric unit, 
A, B, C and D. Molecules A and B interact with each other about a local two-fold axis, 
as do molecules C and D (Fig. S7). The interaction surface is at the edge of the central 
-sheet so that the sheet extends from one protein to its neighbor. Although UL89 
dimers have been detected by cross-linking and gel filtration of the full-length protein 
(8), UL89-C eluted as a monomer in the size-exclusion chromatography. Thus, with the 
data available, it is unclear whether the dimer observed in the crystal structure has any 
physiological relevance or whether it is due to crystal packing. Furthermore, phage and 
herpesvirus terminases are believed to form toroidal structures and assemble as such 
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against the 12-fold portal protein (5, 10), for which a dimer like that observed in the 
crystal structure of UL89-C would not fit. It has been demonstrated by cryo-EM that the 
phage T4 gp17, a homolog of UL89, forms pentamers (15). In the present structure 
there is no evidence of ring formation and it is likely that the oligomerization 
determinants for such an arrangement are outside the UL89-C domain. 
 
UL89 interacts with the UL56 subunit of the terminase. On the basis of results from 
deletion experiments, the amino acids of UL89 proposed to be involved in this 
interaction span from residues 580 to 600 (8). This segment corresponds to the exposed 
helix 4 (Fig. 1 & Fig. S2) and is thus suitable for interaction with UL89 partners. The 
segment includes three residues that are fully conserved among human herpesvirus, 
namely Lys583, Ala586 and Asn595. This observation suggests a similar interaction 
scheme within the family. Furthermore, helix 4 has no counterpart in RNase H or 
integrases, which are enzymes that do not interact with any protein equivalent to UL56.  
 
UL89 as a drug target 
Viral DNA encapsidation machinery has no counterpart in the mammalian cell, thus 
implying that the proteins involved in this process represent promising selective targets 
for antiviral therapy. Several studies have reported that inhibitors of DNA packaging in 
herpesviruses specifically target UL89 and UL56, although the binding sites of the 
proteins have not been elucidated (18-22). Our study demonstrates that the UL89 C-
terminal domain of HCMV and the equivalent domains in all herpesviruses bear the 
essential nuclease function of the terminase for DNA packaging (Fig. 3). We reveal, for 
the first time, the three-dimensional structure of this domain in detail and describe the 
essential residues for the nuclease function, which we demonstrate can be inhibited by 
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raltegravir, a HIV integrase inhibitor approved by the FDA for AIDS treatment in 
October 2007 (37). This study therefore opens a way for the design of further optimized 
inhibitors against UL89-C that may be useful for the development of new anti-herpes 
drugs. 
 
 
 
MATERIALS AND METHODS 
 
Identification of the UL89-C soluble construct from a complete 5′ and 3′ gene 
truncation library. 
The ul89 gene from the HHV5 towne strain comprises two exons; these were amplified, 
cloned separately and subsequently ligated together. The library was constructed as 
described (23). Briefly, for the 5′ deletion library, the gene was cloned into a pET9a-
derived vector out of frame with a TEV-cleavable N-terminal hexahistidine tag 
(MGHHHHHHDYDIPTTENLYFQG) and in frame with a short linker and C-terminal 
biotin acceptor peptide (SNNGSGGGLNDIFEAQKIEWHE). The presence of AatII and 
AscI sites between the hexahistidine tag encoding DNA and the ul89 gene permitted 
unidirectional truncation of the 5′ end of the gene using an exonuclease III. 
Hexahistidine tag fusions of the truncated gene were generated following 
recircularization of the plasmid with T4 DNA ligase. Following transformation, the 
plasmid library was harvested from the E. coli cloning strain (Omnimax T1; Invitrogen) 
and used to transform BL21-CodonPlus-RIL (Stratagene). Robotic processing of the 
library to identify putative soluble expression constructs was done as described (23, 24). 
Briefly, 18,432 colonies comprising 9,216 for the 5′ and 3′ deletion libraries were 
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picked robotically into microtiter plates of TB broth and grown overnight. These were 
gridded robotically onto nitrocellulose membranes over LB agar to grow dense colony 
arrays, which were then induced with IPTG. Colonies were lysed in situ and hybridized 
with Alexa488 Streptavidin (Invitrogen). A fluorimager was used to identify colonies 
expressing biotinylated proteins. The 96 most intense positive clones of each library 
were isolated from the library and grown as 4-ml liquid expression cultures. Nickel 
affinity purifications were performed robotically and purified proteins were assessed by 
SDS-PAGE. 
 
Purification of wild-type and mutant UL89-C proteins. 
E. coli Rosetta cells were transformed with plasmid pHAR-UL89C, pHAR-UL89C-
D463A, pHAR-UL89C-D651A and pHAR-UL89C-D463A-E534A where the biotin 
acceptor peptide had been suppressed by an introduction of a stop codon in the natural 
position. Cells were grown at 37 ºC to an OD600 of 0.5, protein expression was induced 
by addition of IPTG to a final concentration of 0.1 mM with further incubation for 72 h 
at 16 ºC. Cells were harvested at 5000g, re-suspended in binding buffer (50 mM Tris pH 
8, 200 mM NaCl, 20 mM imidazole and 200 μl of DNase I at 2 mg/ml) and sonicated. 
Insoluble material was sedimented by centrifugation (20000g, 4 ºC, 25 min), and the 
supernatant was passed through a 0.45-μm filter. Affinity purification was performed 
with a 5-ml HisTrap HP column (GE Healthcare). The elution was performed with 20 
bed volumes of a linear gradient using a buffer comprising 50 mM Tris pH 8, 200 mM 
NaCl, and 500 mM imidazole. The fractions were analyzed by SDS-PAGE and pooled. 
A second chromatographic step was carried out on a Mono Q column (GE Healthcare) 
using binding buffer consisting of 30 mM Tris pH 8, and 50 mM NaCl. Elution was 
achieved using a linear salt gradient of 50 mM-1 M NaCl. Fractions were analyzed by 
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SDS-PAGE and those that showed higher purity were pooled, concentrated and 
subjected to size-exclusion chromatography using a Superdex 75 10/300 GL column 
(GE Healthcare). The protein eluted at 10.5 ml, corresponding to 31 kDa. Wild-type and 
mutant proteins were expressed and purified with similar efficiencies. 
 
Crystallization and heavy-atom derivatization 
Protein UL89-C was crystallized by mixing 2 μl of protein solution containing 10 
mg/ml of UL89C, 30 mM Tris buffer (pH 8), 50 mM NaCl and 5 mM EDTA with 2 μl 
of precipitant solution containing 10 % (w/v) polyethylene glycol 8000, 150 mM 
calcium acetate hydrate and 100 mM Mes (pH 6), using the sitting drop vapor diffusion 
method. Crystals were flash-cooled in 12 % polyethylene glycol 400 as cryoprotectant. 
To prepare Mn
2+
-derivatised crystals, native crystals were soaked for 1 h in the 
crystallization solution enriched with 50 mM MnCl2. To prepare Hg heavy-atom 
derivatives, native protein crystals were soaked for 24 h in the crystallization solution 
enriched with 0.5 mM ethylmercuricthiosalicylic acid sodium salt. 
 
Structure solution and refinement 
A native data set was collected at the ESRF ID14-2 beamline to a resolution of 2.15 Å. 
Crystals belonged to space group P212121 with cell dimensions a=82.8, b=87.9, c=189.4 
and α=β=γ=90ºC. A data set from a native crystal soaked with Mn2+ was collected at 
ESRF ID29; the crystals belonged to the same space group with the similar cell 
dimensions. In addition, data for an Hg-derivative were collected at ESRF BM16, at a 
wavelength of 1.00726 Å (Hg-bound absorption edge). Native and derivative diffraction 
data were processed using XDS (41), and then scaled, reduced and merged with 
XSCALE (41) (Table S1). Phases were obtained by Single Isomorphous Replacement 
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Anomalous Scattering (SIRAS). SHARP (42) was used to determine the positions of 5 
Hg atoms using data to 3.5 Å, and phasing the data to 2.15 Å. The resulting map was of 
insufficient quality for automatic tracing and most of the polypeptide chain had to be 
built manually using Coot (43). The crystals contained four UL89-C molecules per 
asymmetric unit. Atomic positions and their associated B-factors were refined with 
Refmac5 (44)
 
using non-crystallographic symmetry (NCS) restraints. The model was 
improved by alternating cycles of automatic refinement and interactive model building 
(Fig. S8). The final refinement cycles included TLS refinement. The Mn
2+
-soaked 
crystal structure showed two strong electron density peaks at the active site 
corresponding to the metal ions (Fig. S4). These ions were included and the structure 
refined with Refmac5. The quality of the stereochemistry of the two structures was 
assessed with Procheck (45) (Table S1). 
 
In vitro nuclease assay 
 
Purified wild-type and mutant UL89-C domains (final concentration 2 μM) were 
incubated with 200 ng of circular and  linear (digested with HindIII) pUC18 plasmid 
(2686 bp) in a reaction containing 30 mM Tris pH 8 and 50 mM NaCl for 1 h at 37 ºC. 
The effect of several metal ions was studied by adding 3 mM (final concentration) 
MgCl2, CaCl2 or MnCl2. The activity was terminated by adding EDTA to a final 
concentration of 30 mM. The samples were analyzed by agarose gel electrophoresis 
with ethidium bromide staining. For the inhibitory assay, a range of concentrations of 
raltegravir (Chemietek) were added to the reaction. A stock solution of 5 mM raltegravir 
was prepared at 50% DMSO and was further diluted with 30 mM Tris pH 8, 50 mM 
NaCl to obtain the final concentration. 
 
Miscellaneous 
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Search for folding relatives was performed with MATRAS (46). Structural alignments 
and RMSD calculations were performed with SSM (47). Figures 1, S3, S4, S6, S7 and 
S8 were drawn with Pymol (48). Figure 2 was generate with GRASP (49)
 
and Pymol. 
 
Coordinates. The atomic coordinates for the UL89-C protein structures have been 
deposited with the Protein Data Base under accession codes 3N4P and 3N4Q. 
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 FIGURE LEGENDS 
 
 
Figure 1. (A) Overall structure of UL89-C in a ribbon representation. The metal ions 
are indicated by yellow spheres. UL56-interacting helix 4 is highlighted in 
blue, helices in cyan, 310 helices in green and  strands in magenta. (B) Detailed view 
of the active site area. One Mn
2+
 ion is shown coordinated by Asp463 and Glu534 and a 
second one is coordinated by Asp463 and Glu651. (C) Topology diagram of UL89. 
Color code as in (A). 
 
Figure 2. UL89-C surface representations. (A) Conservation surface of UL89-C based 
on a Risler matrix calculation. Residue color is shown on the basis of conservation score 
within the eight human herpesvirus: orange, more than 80 % similarity; green, full 
conservation. Metal ions are shown in yellow. (B) Electrostatic potential surface of 
UL89-C in the same view as A. The positive potential is shown in blue whereas the 
negative potential is in red. 
 
Figure 3. UL89-C in vitro nuclease assay. (A) Effect of divalent cations on UL89-C 
linear dsDNA nuclease activity. Lane 1: linear (digested with HindIII) pUC18 plasmid 
in the absence of the nuclease. Lane 2: nuclease reaction in the absence of divalent 
cations. Lane 3: nuclease reaction in the presence of Mg
2+
. Lane 4: nuclease reaction in 
the presence of Ca
2+
. Lane 5: nuclease reaction in the presence of Mn
2+
. (B) Effect of 
divalent cations on UL89-C circular dsDNA nuclease activity. Lane 1: circular pUC18 
plasmid in the absence of the nuclease. Lane 2: linear (digested with HindIII) pUC18 
plasmid in the absence of the nuclease. Lane 3: nuclease reaction in the absence of 
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divalent cations. Lane 4: nuclease reaction in the presence of Mg
2+
. Lane 5: nuclease 
reaction in the presence of Ca
2+
. Lane 6: nuclease reaction in the presence of Mn
2+
. (C) 
Nuclease assays with the UL89-C WT and mutant proteins with linear dsDNA. Lane 1: 
linear (digested with HindIII) pUC18 plasmid in absence of the nuclease. Lane 2: 
nuclease assay with the WT proteins. Lane 3: nuclease assay with the D463A mutant. 
Lane 4: nuclease assay with the D651A mutant. Lane 5: nuclease assay with the D463A 
E534A mutant. (D) Nuclease assay with the UL89-C WT and mutant proteins with ds-
circular DNA. Lane 1: circular pUC18 plasmid in absence of the nuclease. Lane 2: 
nuclease assay with the WT protein. Lane 3: nuclease assay with the D463A mutant. 
Lane 4: nuclease assay with the D651A mutant. Lane 5: nuclease assay with the D463A 
E534A mutant. Mutant proteins show only residual nuclease function. Labels: sc, 
supercoiled circular plasmid DNA; ni-oc, nicked open circular plasmid DNA; li, linear 
plasmid DNA. 
 
Figure 4. Inhibition of UL89-C nuclease activity by raltegravir. Lane 1: circular pUC18 
plasmid in the absence of the nuclease. Lane 2: linear (digested with HindIII) pUC18 
plasmid in the absence of the nuclease. Lane 3: nuclease assay with the UL89-C WT 
protein. Lanes 4-14: nuclease assays in the presence of a range of concentrations of 
raltegravir  (0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256 and 512 M).  
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